Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 3/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | POLG | P54098 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25274623 | 1.00 | POLA1 (0.71) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL369565 | 1.00 | POLA1 (0.71) | POLA1PDE4DPDE3ASLC29A1POLG | |
| Gemcitabine Triphosphate SCHEMBL5598638 | 0.98 | POLA1 (0.69) | POLA1PDE4DPDE3ASLC29A1POLG | |
| Gemcitabine Triphosphate SCHEMBL21465271 | 0.98 | POLA1 (0.69) | POLA1PDE4DPDE3ASLC29A1POLG | |
| Gemcitabine Triphosphate SCHEMBL3468704 | 0.98 | POLA1 (0.69) | POLA1PDE4DPDE3ASLC29A1POLG | |
| Gemcitabine Triphosphate SCHEMBL15160598 | 0.98 | POLA1 (0.69) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL22336243 | 0.92 | POLA1 (0.76) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL14677378 | 0.92 | POLA1 (0.76) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL21052582 | 0.92 | POLA1 (0.76) | POLA1PDE4DPDE3ASLC29A1POLG | |
| SCHEMBL16372166 | 0.92 | POLA1 (0.76) | POLA1PDE4DPDE3ASLC29A1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070025910-A1 | Anticancer therapy | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-02-01 | — | — | US | claimed |
| US-9220771-B2 | Peptide for use in the treatment of breast cancer and/or bone metastases | MERCK PATENT GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-8802840-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2014-08-12 | — | — | US | disclosed |
| US-8501699-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-08-06 | — | — | US | disclosed |
| EP-2593122-A1 | PEPTIDE FOR USE IN THE TREATMENT OF BREAST CANCER AND/OR BONE METASTASES | Merck Patent GmbH (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-20130115210-A1 | Peptide for Use in the Treatment of Breast Cancer and/or Bone Metastases | MERCK PATENT GMBH (DE) | 2013-05-09 | — | — | US | disclosed |
| EP-2578225-A1 | Specific Therapy and Medicament Using Integrin Ligands for Treating Cancer | Merck Patent GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-8415309-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGMENT PTY LTD (AT) | 2013-04-09 | — | — | US | disclosed |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20120130146-A1 | CONTINUOUS ADMINISTRATION OF CILENGITIDE IN CANCER TREATMENTS | MERCK PATENT GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20090004138-A1 | Bicyclic Nucleosides and Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-01-01 | — | — | US | disclosed |
| EP-1858889-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-11-28 | — | — | EP | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| WO-2006094347-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2006-09-14 | — | — | WO | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | POLA1 909/4885PDE4D 212/4885PDE3A 765/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | POLA1 909/4885PDE4D 212/4885PDE3A 765/4885 |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | POLA1 2930/4885PDE4D 758/4885PDE3A 2423/4885 |
| US-20090004138-A1 | Bicyclic Nucleosides and Nucleotides as Therapeutic Agents | SLC29A2, NT5C2, NUDT1 | POLA1 132/4885PDE4D 494/4885PDE3A 1181/4885 |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | POLA1 137/4885PDE4D 358/4885PDE3A 1127/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | POLA1 909/4885PDE4D 212/4885PDE3A 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.